Quantitative determination of Cpd118, A novel FBPase inhibitor, in dog plasma by HPLC-MS/MS

Aim: A HPLC-MS/MS method was first developed and validated for the quantification of Cpd118, a novel fructose-1, 6-bisphosphatase inhibitor for controlling gluconeogenesis in Type 2 diabetes mellitus. Materials & methods: Cpd118 was extracted from dog plasma following acetonitrile protein precipitation, separated by HPLC on a CAPCELL PAK ADME column (3.5 mu m, 2.1 mm x 100 mm) and quantified using negative heated electrospray ion source-MS/MS. Results: Cpd118 was quantified from plasma using the method described above over a linear range of 10-20,000 ng/ml, with interday and intraday assay accuracy from -11.78 to 4.01% and the precision was <= 11.15%. Conclusion: The method was sensitive and selective for the quantification of Cpd118 and was successfully used to the pharmacokinetic and bioavailability study of Cpd118 in dogs.

Automated summary

This study developed and validated an HPLC-MS/MS method for quantifying Cpd118, a fructose-1,6-bisphosphatase inhibitor for controlling gluconeogenesis in Type 2 diabetes mellitus. The method was shown to be sensitive, accurate, and successfully applied in pharmacokinetic studies of Cpd118 in dogs.